Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Recruiting 8Unknown 7Not yet recruiting 4Withdrawn 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neuropsychological Tests × Clear all
NCT04835597 2024-08-26

Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

M.D. Anderson Cancer Center

Terminated
27 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01332916 2014-04-25

CANMEM

Centre Francois Baclesse

Phase 2 Terminated
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡